Correlation of magnetic resonance spectroscopy and magnetic resonance imaging with findings of electroencephalography in patients with temporal lobe epilepsy.

INTRODUCTION: This research aimed to see how well magnetic resonance spectroscopy (MRS) could identify the lateralization side in individuals with temporal lobe epilepsy (TLE) compared to electroencephalography (EEG) and magnetic resonance imaging (MRI) results. METHODS: Twenty-three individuals were included in this research and diagnosed with TLE (both clinically and by EEG). Clinical exams, interictal EEG, and MRI were performed on all patients. In addition, the individuals were also subjected to proton MRS. RESULTS: The age range of 23 participants was 20-55 years (mean = 34.6 ± 8.5); 10 were male (44%), and 13 were female (56%). The right temporal lobe MRI showed a sensitivity and specificity of 60% and 55% for detecting mesial temporal lobe sclerosis (MTS) foci, respectively (positive predictive value (PPV) of 27% and negative predictive value (NPV) of 83%). MRI showed 83% sensitivity and 35% specificity for MTS foci in the left temporal lobe (PPV of 31% and NPV of 86%). MRS showed 61% sensitivity and 100% specificity in the right temporal lobe (PPV 100%) and 80% sensitivity and specificity in the left temporal lobe (PPV 100%) for identifying MTS foci. Overall, MRS (both left and right) results matched EEG findings. CONCLUSION: MRS is a potential noninvasive neuroradiology technique for assessing epilepsy patients because it is more sensitive than structural MRI in identifying MTS. The results of the study overall appears to be of interest but still need further support from future studies with larger sample sizes.

Validity of immunohistochemistry method in predicting HER-2 gene status and association of clinicopathological variables with it in invasive breast cancer patients.

Human epidermal growth factor receptor-2 is an important and prognostic factors and one of the most targeted proteins in breast cancer's therapy. There is no globally accepted method for determining its status. Here, we aimed to evaluate the immunohistochemistry method validity in predicting HER-2 status by Fluorescence in situ hybridization method and investigate some clinicopathological variables association with HER-2 amplification. A total of 190 HER-2 2+ and 3+ by immunohistochemistry (IHC) invasive breast cancer cases were enrolled in this study. Fluorescence in situ hybridization (FISH) was performed for these cases using FDA criteria and the association between clinicopathological variables and HER-2 status evaluated. Study consisted of 190 invasive breast cancer patients (160 HER-2 2+ and 30 HER-2 3+). HER-2 FISH amplification according to FDA criteria was found 27.5% (44/160 patients) in HER-2 2+ patients and 83.3% (25/30 patients) in HER-2 3+ patients. Tumors with HER-2 amplification were more likely to be ER-negative (51.0% vs 31.2%, p = 0.013) and PR-negative (52.9% vs 27.0%, p < 0.001). This study showed that immunohistochemistry is not a good method for evaluating HER-2 status and decision-making about trastuzumab therapy even with 3+ score patients. However, this result may not be too strong for IHC 3+ cases due to the limited number of these patients in this study.